核醫藥物鎝(V) - 99m雙硫醇琥珀酸(Tc(V) - 99m DMS)製劑體外穩定性的研究

Tc(V)-99m DMS, developed by Yokoyama et al. in 1981, has been recognized to be advan-tageous for the scintigraphic diagnosis of vari-ous malignant tumors and their metastasis. The aim of this study is to assess the in-vitro stabili-ty of Tc(V)-99m DMS. Thin-alyer chroma-tography, including paper chromatography and silica gel thn layer chromatography, is perfor-med to determine the change of radiochemical species presented in the reconstituted solution of Tc(V)-99m DMS prepared from the DMS kit (Institute of Nuclear Energy Research, Atomic Energy Council R.O.C.) and the commercial DMSA kit (Nephroscint, IRE CELLTARG Radiopharmaceuticals Japan). The bioscan ima-ging scanner is used to measure the Rf value and labeling efficiency of radiochemical species on the chromatographic strip. The in-vitro sta-bility of Tc(V)-99m DMS prepared from the DMS kit and the commercial DMSAS kit is stu-died by examining various parameters which in-clude temperature(˚C) and time(hr)after recon-stitution. The results show that the in-vitro sta-bility of Tc(V)-99m DMS prepared from the DMS kit is actually better than that from the commercial DMSA kit. The one-step labeling method of DMS kit is much simpler than the two-step labeling method of DMSA kit.